Highland Peak Capital LLC Sells 343,115 Shares of Grifols, S.A. (NASDAQ:GRFS)

Highland Peak Capital LLC reduced its position in Grifols, S.A. (NASDAQ:GRFS) by 36.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 607,096 shares of the biotechnology company’s stock after selling 343,115 shares during the quarter. Grifols makes up 2.4% of Highland Peak Capital LLC’s portfolio, making the stock its 9th largest holding. Highland Peak Capital LLC’s holdings in Grifols were worth $5,391,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Capital World Investors grew its holdings in shares of Grifols by 4.9% in the 1st quarter. Capital World Investors now owns 20,749,225 shares of the biotechnology company’s stock worth $138,605,000 after purchasing an additional 961,700 shares during the last quarter. Brandes Investment Partners LP raised its stake in shares of Grifols by 8.7% in the second quarter. Brandes Investment Partners LP now owns 18,596,790 shares of the biotechnology company’s stock worth $117,242,000 after acquiring an additional 1,481,924 shares during the last quarter. Black Creek Investment Management Inc. lifted its position in shares of Grifols by 7.7% during the second quarter. Black Creek Investment Management Inc. now owns 12,339,314 shares of the biotechnology company’s stock worth $77,799,000 after purchasing an additional 881,155 shares in the last quarter. Armistice Capital LLC raised its position in Grifols by 18.7% in the 2nd quarter. Armistice Capital LLC now owns 7,892,000 shares of the biotechnology company’s stock worth $49,759,000 after purchasing an additional 1,244,000 shares during the last quarter. Finally, Whitebox Advisors LLC raised its position in Grifols by 45.6% in the 2nd quarter. Whitebox Advisors LLC now owns 2,702,390 shares of the biotechnology company’s stock worth $17,039,000 after purchasing an additional 846,940 shares during the last quarter.

Analysts Set New Price Targets

Separately, Berenberg Bank upgraded Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

Grifols Trading Up 1.7 %

Shares of GRFS stock opened at $8.60 on Thursday. The firm has a fifty day moving average of $8.87 and a 200-day moving average of $8.04. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. Grifols, S.A. has a 12-month low of $5.30 and a 12-month high of $12.15.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.